Clinical trials
Peripheral Blood Stem Cell Transplantation clinical trials
Below are recruiting peripheral blood stem cell transplantation clinical trials, each written for real people, not researchers. We’re tracking 178 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06869265RecruitingPhase 2
Thiotepa added to standard chemo before a stem cell transplant for older adults with high-risk AML
This trial tests whether adding a drug called thiotepa to the usual chemotherapy (busulfan and fludarabine) before a half-matched stem cell transplant can safely and effectively treat older adults (55–70) with high-risk AML.
Beijing, Beijing MunicipalityAges 55–70 - NCT06879847Recruiting
Clinical trial of radiation and chemotherapy before stem cell transplant for hard-to-treat AML
This trial tests a combination of total body irradiation and two chemotherapy drugs (busulfan and melphalan) given before a stem cell transplant. It is for people with acute myeloid leukemia that has come back or not responded to standard treatment.
Suzhou, JiangsuAges 14–70 - NCT07059026Recruiting
Thrombotic microangiopathy after stem cell transplant in adults
This study looks at people who have a blood clotting problem called TMA after a stem cell transplant from a donor. It gathers information from routine checkups to learn more about this condition.
Buenos AiresAges 18 years+ - NCT07297173RecruitingPhase 1
Immune cell infusion plus transplant for tough leukemia
This trial tests a new two-step approach for people with hard-to-treat leukemia. First, you get chemotherapy plus an infusion of special immune cells from a partially matched donor, then a stem cell transplant. The goal is to see if this is safe and helps the leukemia go away.
BeijingAges 15 years+ - NCT01861106RecruitingPhase 2
Bone marrow transplant for people with GATA2 gene changes
This trial tests whether an allogeneic bone marrow (stem cell) transplant can improve outcomes for people with GATA2 gene changes or “MonoMAC” syndrome. It aims to rebuild a healthier immune system in patients who have serious infections and immune cell deficiencies.
Bethesda, MarylandAges 6–70 - NCT07006506RecruitingPhase 2
Belumosudil to prevent graft-versus-host disease after transplant
This study tests whether a drug called belumosudil can help prevent graft-versus-host disease (GVHD) after a stem cell transplant. It is for people who have had a recent transplant and are at risk for GVHD.
Basking Ridge, New JerseyAges 18 years+ - NCT07500753Recruiting
Study of a conditioning regimen for older adults with hard-to-treat leukemia or MDS
This trial tests a chemotherapy combination (Clad-LABU) to prepare older patients for a stem cell transplant. It is for people aged 50 or older with relapsed or refractory AML or high-risk MDS.
Suzhou, JiangsuAges 50 years+ - NCT07509749RecruitingPhase 2
New treatments for severe acute GVHD after stem cell transplant
This trial tests new medications for people who develop severe acute graft-versus-host disease (aGVHD) within 100 days after their first stem cell transplant. The goal is to find safer, more effective ways to control aGVHD and improve recovery.
BeijingAges 14 years+ - NCT07670468RecruitingPhase 1/Phase 2
T-cell therapy for resistant viral infections after transplant or cancer treatment
This trial tests a special T-cell treatment (LB-DTK-MV) for people with virus infections (CMV, BKV, EBV) that did not get better with standard medicines. It is for patients who had a stem cell transplant or certain cancer therapies like CAR-T or bispecific antibodies.
SeoulAges 19 years+ - NCT05674539Enrolling by invitationPhase 3
Less intense transplant regimen for AML or MDS patients
This trial tests whether a less intense chemotherapy and transplant plan can work for adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who are getting a stem cell transplant. It may help reduce transplant-related harm, especially in people considered higher risk due to age or other health factors.
Wuhan, HubeiAges 18 years+ - NCT04512534RecruitingPhase 2
Check-in study of immunotherapy plus another drug for lymphoma
This Phase 2 trial tests whether combining sintilimab (an immunotherapy) with chidamide (an anticancer “epigenetic” drug) can shrink peripheral T-cell lymphoma that has come back or didn’t respond. It’s for adults who have measurable lymphoma spots and can safely take both medicines.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05572983RecruitingPhase 2
New treatment for a specific T-cell lymphoma type
This Phase 2 trial tests chidamide plus CHOP chemotherapy in people who have not received any prior treatment for a certain type of peripheral T-cell lymphoma. The study aims to shrink the lymphoma and improve outcomes while checking for side effects and safety.
Guangzhou, GuangdongAges 18–75 - NCT02356653RecruitingEarly Phase 1
Stem cell transplant help for children lacking a matching sibling
This expanded-access study offers a specific type of stem cell transplant preparation that removes certain immune cells (CD3 and CD19) from donor stem cells. It is for children who need a transplant but do not have a fully matched sibling donor and whose team cannot use the hospital’s usual matching device protocol.
Philadelphia, PennsylvaniaAges Up to 30 years - NCT06776952RecruitingPhase 3
Study of XNW5004 for relapsed or refractory peripheral T-cell lymphoma
This study tests a new oral tablet called XNW5004 for people with peripheral T-cell lymphoma (a type of blood cancer) that has come back or not responded to prior treatments. The goal is to see if this drug can help shrink tumors or slow the disease.
Beijing, Beijing MunicipalityAges 3 weeks–2 months - NCT05182957RecruitingPhase 2
Study of anti-PD-1, lenalidomide, and azacitidine for PTCL
This trial tests a combination of three medicines (anti-PD-1, lenalidomide, and azacitidine) for adults with relapsed or refractory peripheral T-cell lymphoma (PTCL) that is measurable or growing. It aims to shrink lymphoma and improve control of the disease when standard treatments haven’t worked or have stopped working.
Suzhou, JiangsuAges 18 years+ - NCT06947967RecruitingPhase 3
Tucidinostat plus CHOP for newly diagnosed PTCL-TFH lymphoma
This trial tests a new drug (tucidinostat) added to standard chemotherapy (CHOP) for people newly diagnosed with a specific type of lymphoma called PTCL-TFH. It aims to see if the combination works better than standard treatment alone.
Guangzhou, GuangdongAges 18–80 - NCT07164560RecruitingPhase 1
CAR-NK cell therapy for relapsed T-cell lymphoma
This trial tests a new treatment using immune cells (CAR-NK) made from donated cord blood. These cells are designed to find and attack T-cell lymphoma that has come back or not responded to other treatments. The goal is to see if this approach is safe and effective.
Hangzhou, ZhejiangAges 18–75 - NCT06996119RecruitingPhase 1
Preventing graft-versus-host disease after stem cell transplant
This trial tests adding a drug called emapalumab to standard medications (cyclophosphamide, tacrolimus, mycophenolate mofetil) to prevent graft-versus-host disease in adults receiving a donor stem cell transplant. This approach aims to reduce complications after transplant.
Duarte, CaliforniaAges 18–75 - NCT06128070RecruitingPhase 2
Preventing GVHD after stem cell transplant for leukemia
This trial tests adding ruxolitinib to standard drugs (tacrolimus and methotrexate) to prevent graft-versus-host disease in children and young adults undergoing a stem cell transplant for acute leukemia or myelodysplastic syndrome. The goal is to lower the risk of GVHD and improve transplant outcomes.
Duarte, CaliforniaAges 2–22 - NCT07730515RecruitingPhase 1/Phase 2
Study of XNW5004 plus chemo for untreated T-cell lymphoma
This trial tests a new drug called XNW5004 combined with standard chemotherapy for people who have just been diagnosed with peripheral T-cell lymphoma and haven't had treatment yet. The goal is to see if adding XNW5004 helps more than chemotherapy alone.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07750886Recruiting
Collecting samples for lymphoma research
This study collects blood and tumor tissue samples from people newly diagnosed with aggressive non-Hodgkin lymphoma who will receive standard chemotherapy. The goal is to improve future tests for detecting minimal residual disease (tiny amounts of cancer left after treatment).
Austin, TexasAges 18 years+ - NCT05833724RecruitingPhase 2
Chidamide for relapsed or resistant peripheral T-cell lymphoma
This trial tests chidamide (a targeted medicine that affects how cells manage gene activity) in people whose peripheral T-cell lymphoma has come back or did not respond to treatment. It may help shrink measurable tumors and control the disease after prior therapies.
Kaohsiung CityAges 20–75 - NCT06495723RecruitingPhase 1/Phase 2
Antibody therapy for relapsed T-cell lymphoma
This trial tests a new experimental antibody therapy for people with certain types of peripheral T-cell lymphoma that have not responded to or have come back after prior treatment. The study aims to see if the treatment is safe and effective.
CaenAges 18 years+ - NCT04812431RecruitingPhase 1/Phase 2
Tested stem cell transplant therapy for severe spinal cord injury
This trial tests a cell transplant approach for people with a very severe spinal cord injury. It focuses first on safety and also looks for early signs the therapy may improve function.
Suwon, GyeonggidoAges 18–65
Hear when a new Peripheral Blood Stem Cell Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for peripheral blood stem cell transplantation?
- Yes. Clin2 currently lists 178 recruiting peripheral blood stem cell transplantation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a peripheral blood stem cell transplantation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a peripheral blood stem cell transplantation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Hematopoietic Stem Cell Transplantation
- Allogeneic Hematopoietic Stem Cell Transplantation
- Stem Cell Transplantation
- Hematopoetic Stem Cell Transplantation
- Allogeneic Stem Cell Transplantation
- Allogeneic Hematopoietic Stem Cell Transplantation Recipient
- Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
- Haploidentical Hematopoietic Stem Cell Transplantation
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.